{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:29:20Z","timestamp":1793996960981,"version":"4.8.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI164561"],"award-info":[{"award-number":["UM1AI164561"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI178376"],"award-info":[{"award-number":["P01AI178376"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI164561"],"award-info":[{"award-number":["UM1AI164561"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI178376"],"award-info":[{"award-number":["P01AI178376"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41591-025-04139-y","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:04:02Z","timestamp":1770890642000},"page":"505-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy"],"prefix":"10.1038","volume":"32","author":[{"given":"Aarthi","family":"Talla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao L. L. C.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Pacheco","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam N.","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saswat Kumar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Schuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khader","family":"Ghneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajantha","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-5250","authenticated-orcid":false,"given":"Frank","family":"Maldarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-1395","authenticated-orcid":false,"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-4675","authenticated-orcid":false,"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-9719","authenticated-orcid":false,"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-7297","authenticated-orcid":false,"given":"Leonard","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-2129","authenticated-orcid":false,"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-5018","authenticated-orcid":false,"given":"Nicolas","family":"Chomont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-8241","authenticated-orcid":false,"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-747X","authenticated-orcid":false,"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-0153","authenticated-orcid":false,"given":"Steven P.","family":"Fling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Cheever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Uldrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-7046","authenticated-orcid":false,"given":"Ashish A.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-4828","authenticated-orcid":false,"given":"Rafick-Pierre","family":"Sekaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"4139_CR1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","volume":"21","author":"RJ Landovitz","year":"2023","unstructured":"Landovitz, R. J., Scott, H. & Deeks, S. G. Prevention, treatment and cure of HIV infection. Nat. Rev. Microbiol. 21, 657\u2013670 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"4139_CR2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/44755","volume":"401","author":"TW Chun","year":"1999","unstructured":"Chun, T. W., Davey, R. T., Engel, D., Lane, H. C. & Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874\u2013875 (1999).","journal-title":"Nature"},{"key":"4139_CR3","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","volume":"96","author":"RT Davey","year":"1999","unstructured":"Davey, R. T.Jr et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109\u201315114 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4139_CR4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295\u20131300 (1997).","journal-title":"Science"},{"key":"4139_CR5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","volume":"5","author":"D Finzi","year":"1999","unstructured":"Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512\u2013517 (1999).","journal-title":"Nat. Med."},{"key":"4139_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11904-011-0106-4","volume":"9","author":"F Porichis","year":"2012","unstructured":"Porichis, F. & Kaufmann, D. E. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr. HIV\/AIDS Rep. 9, 81\u201390 (2012).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"4139_CR7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/COH.0000000000000230","volume":"11","author":"M Massanella","year":"2016","unstructured":"Massanella, M., Fromentin, R. & Chomont, N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr. Opin. HIV AIDS 11, 234\u2013241 (2016).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"4139_CR8","doi-asserted-by":"crossref","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","volume":"12","author":"R Fromentin","year":"2016","unstructured":"Fromentin, R. et al. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 12, e1005761 (2016).","journal-title":"PLoS Pathog."},{"key":"4139_CR9","doi-asserted-by":"crossref","first-page":"101471","DOI":"10.1016\/j.smim.2021.101471","volume":"51","author":"CW Cai","year":"2021","unstructured":"Cai, C. W. & Sereti, I. Residual immune dysfunction under antiretroviral therapy. Semin. Immunol. 51, 101471 (2021).","journal-title":"Semin. Immunol."},{"key":"4139_CR10","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.179.3.1979","volume":"179","author":"M D\u2019Souza","year":"2007","unstructured":"D\u2019Souza, M. et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179, 1979\u20131987 (2007).","journal-title":"J. Immunol."},{"key":"4139_CR11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893\u2013900 (2009).","journal-title":"Nat. Med."},{"key":"4139_CR12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","volume":"32","author":"VA Evans","year":"2018","unstructured":"Evans, V. A. et al. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS 32, 1491\u20131497 (2018).","journal-title":"AIDS"},{"key":"4139_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08798-7","volume":"10","author":"R Fromentin","year":"2019","unstructured":"Fromentin, R. et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nat. Commun. 10, 814 (2019).","journal-title":"Nat. Commun."},{"key":"4139_CR14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345\u2013359 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"4139_CR15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"4139_CR16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"4139_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"4139_CR18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198\u20131202 (2006).","journal-title":"Nat. Med."},{"key":"4139_CR19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350\u2013354 (2006).","journal-title":"Nature"},{"key":"4139_CR20","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20061496","volume":"203","author":"C Petrovas","year":"2006","unstructured":"Petrovas, C. et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203, 2281\u20132292 (2006).","journal-title":"J. Exp. Med."},{"key":"4139_CR21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0000000000002406","volume":"34","author":"BJC Macatangay","year":"2020","unstructured":"Macatangay, B. J. C. et al. T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. AIDS 34, 15\u201324 (2020).","journal-title":"AIDS"},{"key":"4139_CR22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","volume":"458","author":"V Velu","year":"2009","unstructured":"Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206\u2013210 (2009).","journal-title":"Nature"},{"key":"4139_CR23","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1172\/JCI60612","volume":"122","author":"R Dyavar Shetty","year":"2012","unstructured":"Dyavar Shetty, R. et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Invest. 122, 1712\u20131716 (2012).","journal-title":"J. Clin. Invest."},{"key":"4139_CR24","doi-asserted-by":"crossref","unstructured":"Mylvaganam, G. H. et al. Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. JCI Insight 3, e122940 (2018).","DOI":"10.1172\/jci.insight.122940"},{"key":"4139_CR25","doi-asserted-by":"crossref","unstructured":"Rahman, S. A. et al. PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue. Science Immunol. 6, eabh3034 (2021).","DOI":"10.1126\/sciimmunol.abh3034"},{"key":"4139_CR26","doi-asserted-by":"crossref","first-page":"2202148119","DOI":"10.1073\/pnas.2202148119","volume":"119","author":"V Velu","year":"2022","unstructured":"Velu, V. et al. PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques. Proc. Natl Acad. Sci. USA 119, 2202148119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4139_CR27","doi-asserted-by":"crossref","first-page":"1332\u22121339","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick, T. S. et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study. JAMA Oncol. 5, 1332\u22121339 (2019).","journal-title":"JAMA Oncol."},{"key":"4139_CR28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11904-020-00525-y","volume":"17","author":"K Lurain","year":"2020","unstructured":"Lurain, K., Ramaswami, R., Yarchoan, R. & Uldrick, T. S. Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer. Curr. HIV\/AIDS Rep. 17, 547\u2013556 (2020).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"4139_CR29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(22)00097-3","volume":"23","author":"J Delyon","year":"2022","unstructured":"Delyon, J. et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi\u2019s sarcoma: a multicentre, single-arm, phase 2 study. Lancet. Oncol. 23, 491\u2013500 (2022).","journal-title":"Lancet. Oncol."},{"key":"4139_CR30","doi-asserted-by":"crossref","unstructured":"Uldrick, T. S. et al. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Science Transl. Med. 14, eabl3836 (2022).","DOI":"10.1126\/scitranslmed.abl3836"},{"key":"4139_CR31","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1097\/QAI.0000000000002716","volume":"87","author":"CL Gay","year":"2021","unstructured":"Gay, C. L. et al. Suspected immune-related adverse events with an anti-PD-1 inhibitor in otherwise healthy people with HIV. J. Acquir. Immune Defic. Syndr. 87, e234\u2013e236 (2021).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"4139_CR32","doi-asserted-by":"crossref","DOI":"10.1186\/gm327","volume":"4","author":"G Gundem","year":"2012","unstructured":"Gundem, G. & Lopez-Bigas, N. Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer types. Genome Med. 4, 28 (2012).","journal-title":"Genome Med."},{"key":"4139_CR33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41577-021-00563-6","volume":"22","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Shan, Q. & Xue, H. H. TCF1 in T cell immunity: a broadened frontier. Nat. Rev. Immunol. 22, 147\u2013157 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"4139_CR34","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1073\/pnas.1308953111","volume":"111","author":"ME Gonzalez","year":"2014","unstructured":"Gonzalez, M. E. et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl Acad. Sci. USA 111, 3098\u20133103 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4139_CR35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41586-024-08411-y","volume":"638","author":"G Heimberg","year":"2025","unstructured":"Heimberg, G. et al. A cell atlas foundation model for scalable search of similar human cells. Nature 638, 1085\u20131094 (2025).","journal-title":"Nature"},{"key":"4139_CR36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods 17, 159\u2013162 (2020).","journal-title":"Nat. Methods"},{"key":"4139_CR37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"4139_CR38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ccell.2024.12.008","volume":"43","author":"A Acha-Sagredo","year":"2025","unstructured":"Acha-Sagredo, A. et al. A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. Cancer Cell 43, 292\u2013307 (2025).","journal-title":"Cancer Cell"},{"key":"4139_CR39","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).","journal-title":"Science"},{"key":"4139_CR40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12865-024-00651-x","volume":"25","author":"Q Geng","year":"2024","unstructured":"Geng, Q. et al. \u03b2-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer. BMC Immunol. 25, 60 (2024).","journal-title":"BMC Immunol."},{"key":"4139_CR41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00262-022-03276-4","volume":"72","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. PD-L1 antibody enhanced beta-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. Cancer Immunol. Immunother. 72, 719\u2013731 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"4139_CR42","volume":"279","author":"Q Song","year":"2024","unstructured":"Song, Q. et al. A \u03b2-1,3\/1,6-glucan enhances anti-tumor effects of PD1 antibody by reprogramming tumor microenvironment. Int. J. Biol. Macromol. 279, 134660 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"4139_CR43","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. \u03b2-glucan combined with PD-1\/PD-L1 checkpoint blockade for immunotherapy in patients with advanced cancer. Front. Pharmacol. 13, 887457 (2022).","journal-title":"Front. Pharmacol."},{"key":"4139_CR44","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. \u03b2-glucan: a potent adjuvant in immunotherapy for digestive tract tumors. Front. Immunol. 15, 1424261 (2024).","journal-title":"Front. Immunol."},{"key":"4139_CR45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nature13554","volume":"511","author":"NG Sandler","year":"2014","unstructured":"Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601\u2013605 (2014).","journal-title":"Nature"},{"key":"4139_CR46","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.cell.2021.05.039","volume":"184","author":"F Wimmers","year":"2021","unstructured":"Wimmers, F. et al. The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell 184, 3915\u20133935 (2021).","journal-title":"Cell"},{"key":"4139_CR47","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41590-022-01262-7","volume":"23","author":"GM Boukhaled","year":"2022","unstructured":"Boukhaled, G. M. et al. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat. Immunol. 23, 1273\u20131283 (2022).","journal-title":"Nat. Immunol."},{"key":"4139_CR48","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687 (2006).","journal-title":"Nature"},{"key":"4139_CR49","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/QAD.0000000000003201","volume":"36","author":"CV Fletcher","year":"2022","unstructured":"Fletcher, C. V. et al. Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression. AIDS 36, 985\u2013990 (2022).","journal-title":"AIDS"},{"key":"4139_CR50","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","volume":"6","author":"M Gonzalez-Cao","year":"2020","unstructured":"Gonzalez-Cao, M. et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study. JAMA Oncol. 6, 1063\u20131067 (2020).","journal-title":"JAMA Oncol."},{"key":"4139_CR51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/aid.2020.0243","volume":"37","author":"E Papasavvas","year":"2021","unstructured":"Papasavvas, E. et al. Safety, immune, and antiviral effects of pegylated interferon alpha 2b administration in antiretroviral therapy-suppressed individuals: results of pilot clinical trial. AIDS Res. Hum. Retroviruses 37, 433\u2013443 (2021).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"4139_CR52","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002961","volume":"35","author":"E Papasavvas","year":"2021","unstructured":"Papasavvas, E. et al. Comparable HIV suppression by pegylated-IFN-\u03b12a or pegylated-IFN-\u03b12b during a 4-week analytical treatment interruption. AIDS 35, 2051\u20132054 (2021).","journal-title":"AIDS"},{"key":"4139_CR53","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","volume":"28","author":"JS Miller","year":"2022","unstructured":"Miller, J. S. et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat. Med. 28, 392\u2013400 (2022).","journal-title":"Nat. Med."},{"key":"4139_CR54","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle, J. M. et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 19, 694\u2013704 (2018).","journal-title":"Lancet Oncol."},{"key":"4139_CR55","doi-asserted-by":"crossref","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","volume":"9","author":"S Sanjabi","year":"2017","unstructured":"Sanjabi, S., Oh, S. A. & Li, M. O. Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol. 9, a022236 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"4139_CR56","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.1701325","volume":"200","author":"JR Grunwell","year":"2018","unstructured":"Grunwell, J. R. et al. TGF-\u03b21 suppresses the type I IFN response and induces mitochondrial dysfunction in alveolar macrophages. J. Immunol. 200, 2115\u20132128 (2018).","journal-title":"J. Immunol."},{"key":"4139_CR57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11998-w","volume":"10","author":"MV Guerin","year":"2019","unstructured":"Guerin, M. V. et al. TGF\u03b2 blocks IFN\u03b1\/\u03b2 release and tumor rejection in spontaneous mammary tumors. Nat. Commun. 10, 4131 (2019).","journal-title":"Nat. Commun."},{"key":"4139_CR58","doi-asserted-by":"crossref","first-page":"e003519","DOI":"10.1136\/jitc-2021-003519","volume":"10","author":"P Hamon","year":"2022","unstructured":"Hamon, P. et al. TGF\u03b2 receptor inhibition unleashes interferon-\u03b2 production by tumor-associated macrophages and enhances radiotherapy efficacy. J. Immunother. Cancer 10, e003519 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"4139_CR59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/jir.2022.0132","volume":"42","author":"T Gauthier","year":"2022","unstructured":"Gauthier, T. & Chen, W. IFN-\u03b3 and TGF-\u03b2, crucial players in immune responses: a tribute to Howard Young. J. Interferon Cytokine Res. 42, 643\u2013654 (2022).","journal-title":"J. Interferon Cytokine Res."},{"key":"4139_CR60","volume":"97","author":"LY Yim","year":"2023","unstructured":"Yim, L. Y. et al. Transforming growth factor \u03b2 signaling promotes HIV-1 infection in activated and resting memory CD4+ T cells. J. Virol. 97, e0027023 (2023).","journal-title":"J. Virol."},{"key":"4139_CR61","doi-asserted-by":"crossref","unstructured":"Kulpa, D. A. et al. Differentiation into an effector memory phenotype potentiates HIV-1 latency reversal in CD4+ T cells. J. Virol. 93, e00969-19 (2019).","DOI":"10.1128\/JVI.00969-19"},{"key":"4139_CR62","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","volume":"26","author":"G Monaco","year":"2019","unstructured":"Monaco, G. et al. RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell Rep. 26, 1627\u20131640 (2019).","journal-title":"Cell Rep."},{"key":"4139_CR63","doi-asserted-by":"crossref","first-page":"e116306","DOI":"10.1371\/journal.pone.0116306","volume":"9","author":"M Somsouk","year":"2014","unstructured":"Somsouk, M. et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS ONE 9, e116306 (2014).","journal-title":"PLoS ONE"},{"key":"4139_CR64","doi-asserted-by":"crossref","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","volume":"10","author":"JH Elliott","year":"2014","unstructured":"Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).","journal-title":"PLoS Pathog."},{"key":"4139_CR65","doi-asserted-by":"crossref","unstructured":"Zerbato, J. M. et al. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. eBioMedicine 65, 103241 (2021).","DOI":"10.1016\/j.ebiom.2021.103241"},{"key":"4139_CR66","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"4139_CR67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"4139_CR68","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337 (2019).","journal-title":"Cell Syst."},{"key":"4139_CR69","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-015-0844-5","volume":"16","author":"G Finak","year":"2015","unstructured":"Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).","journal-title":"Genome Biol."},{"key":"4139_CR70","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc. Ser. B Methodol. 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"4139_CR71","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"4139_CR72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4139_CR73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"4139_CR74","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2010-11-12-144","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"4139_CR75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"4139_CR76","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4139_CR77","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"4139_CR78","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/bioinformatics\/btq466","volume":"26","author":"A Lachmann","year":"2010","unstructured":"Lachmann, A. et al. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26, 2438\u20132444 (2010).","journal-title":"Bioinformatics"},{"key":"4139_CR79","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"4139_CR80","doi-asserted-by":"crossref","first-page":"e1005752","DOI":"10.1371\/journal.pcbi.1005752","volume":"13","author":"F Rohart","year":"2017","unstructured":"Rohart, F., Gautier, B., Singh, A. & L\u00ea Cao, K. A. mixOmics: an R package for \u02bcomics feature selection and multiple data integration. PLoS Comput. Biol. 13, e1005752 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"4139_CR81","doi-asserted-by":"publisher","unstructured":"Sharma, A. Code and data for manuscript: blocking PD-1 engagement rapidly upregulates innate antiviral and immune functions that associate with HIV reservoir decay. Zenodo https:\/\/doi.org\/10.5281\/zenodo.11200738 (2024).","DOI":"10.5281\/zenodo.11200738"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04139-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04139-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04139-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:03:38Z","timestamp":1771783418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04139-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4139"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04139-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.Y., R.R. and K.L. report receiving research support from Celgene (now Bristol Myers Squibb), CTI BioPharma (a Sobi A.B. company), PDS Biotech and Janssen Pharmaceuticals through Cooperative Research and Development Agreements (CRADAs) with the NCI. R.Y., R.R. and K.L. also report receiving drugs for clinical trials from Merck, EMD-Serano and Lilly and preclinical material from Lentigen Technology through CRADAs or Material Transfer Agreements (MTAs) with the NCI. R.Y. is a co-inventor on US Patent 10,001,483 titled \u2018Methods for the treatment of Kaposi\u2019s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds and uses of biomarkers\u2019. An immediate family member of R.Y. is a co-inventor on patents or patent applications related to internalization of target receptors, epigenetic analysis and ephrin tyrosine kinase inhibitors. All rights, titles and interests to these patents have been assigned to the US Department of Health and Human Services; the government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). S.R.L. receives honoraria from Gilead Sciences, Merck, AbbVie, Esfam and Immunocore as a member of their scientific advisory boards. J.M.-P. has received research funding, consultancy fees and lecture sponsorships from and has served on advisory boards for various companies (Merck Sharp & Dohme, Gilead Sciences, Grifols and ViiV Healthcare) outside the scope of this article. T.S.U. is a full-time employee of Regeneron Pharmaceuticals. A.T. and A.N.P. are independent consultants and list their consulting entities as primary affiliations that have no financial or commercial interest in the subject matter of this study. S.G.D. receives research support from Gilead. He is also a member of the scientific advisory board for Tendel. S.G.D. has consulted for AbbVie, Hologic and ViiV. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}